List of sessions not to be missed in sarcoma at ESMO 2024 by Shushan Hovsepyan
Shushan Hovsepyan shared on LinkedIn:
“The ESMO 2024 author’s list is now available and this is my list of sessions not to be missed in sarcoma.
• Desmoid-type Fibromatosis: To treat or not to treat? |Bernd Kasper, Alessandro Gronchi
• New developments in the treatment of bone sarcomas |Sandra Strauss
• Landmark trials in immunotherapy |Breelyn Wilky
• Landmark trials in bone and joint sarcomas (incl. LPS/LMS) |Silvia Stacchiotti
• New Developments in the treatment of soft tissue sarcomas |Kjetil Boye
• Landmark Trials in soft tissue sarcoma |Robin Jones
• 1726MO – Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study |Breelyn Wilky,
• 1718O – EREMISS Trial: A double-blind placebo-controlled randomized trial assessing efficacy/safety of Regorafenib as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma patients |Nicolas Penel
• 1720MO – A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma |Evan Rosenbaum
Source: Shushan Hovsepyan/Linkedin
Shushan Hovsepyan is a pediatric oncologist and adjunct assistant professor at the Yerevan State Medical University. Currently, she is the Editor-in-Chief of OncoDaily Medical Journal.
She completed her clinical fellowship at the National Institute of Cancer in Milan, Italy and at the St. Anna Children’s Research Hospital in Austria Furthermore, she held a research fellowship position at the European Organisation for Research and Treatment of Cancer in Brussels, Belgium.
Dr. Hovsepyan also completed the Postgraduate Harvard Medical School’s Effective Writing for Healthcare program. She is a former co-chair of the SIOP Global Health Network Education and Training Working Group.